

April 14, 2023  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company's Directors

Symbio Pharmaceuticals Limited (“the Company”) today announced the following details regarding the issuance of stock acquisition rights to the Company’s Directors (the 59th Series Symbio Stock Options) pursuant to the resolution approved at the Board of Directors’ meeting held on March 23, 2023. The issuance of the stock acquisition rights does not constitute a favorable issuance.

1. Number of stock acquisition rights  
3,160 units (in total for 4 directors, excluding directors who are Audit and Supervisory Committee members)
2. Class and number of shares to be issued upon exercise of the stock acquisition rights  
The Company’s common stock: 79,000 shares
3. Amount to be paid for the stock acquisition rights and calculation method
  - (1) Amount to be paid per unit: 11,000 yen
  - (2) Amount to be paid per share: 440 yen

As the amount to be paid for the stock acquisition rights is provided to the recipient in lieu of compensation, each recipient is required to waive his or her claim to the corresponding amount of compensation against the Company..

(Note)

For further information regarding the stock acquisition rights, please refer to the Company’s press release dated March 23, 2023 titled “Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors.”

### [Contact]

Investor Relations

Tel: +81(0)3 5472 1125